SCHEMBL4511217

SCHEMBL4511217

O=C1C(Cc2ccc(NS(=O)(=O)c3ccccc3)cc2Cl)CCN1C1CCCCC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.52
GAA P10253 2/20 0.43
TSHR P16473 1/20 0.43
KMT2A Q03164 4/20 0.43
ALDH1A1 P00352 4/20 0.43
MEN1 O00255 3/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
HTR6 P50406 3/20 0.41
LMNA P02545 3/20 0.40
HTT P42858 3/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
BRD4 O60885 2/20 0.39
MAPT P10636 2/20 0.39
KDM4E B2RXH2 1/20 0.39
DDB1 Q16531 1/20 0.38
CRBN Q96SW2 1/20 0.38
HPGD P15428 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2999199 0.88 HSD11B1 (0.54) HSD11B1GAATSHRKMT2AALDH1A1
SCHEMBL4524568 0.86 GAA (0.47) HSD11B1GAAHPGD
SCHEMBL3000838 0.85 HSD11B1 (0.57) HSD11B1ALDH1A1LMNA
SCHEMBL13955165 0.84 HSD11B1 (0.47) HSD11B1GAATSHRKMT2AALDH1A1
SCHEMBL4500819 0.83 HSD11B1 (0.45) HSD11B1GAATSHRKMT2AALDH1A1
SCHEMBL4516764 0.82 HSD11B1 (0.60) HSD11B1TSHRLMNAHTTBRD4
SCHEMBL4514220 0.81 HSD11B1 (0.51) HSD11B1TSHRALDH1A1LMNAHTT
SCHEMBL4511944 0.81 HSD11B1 (0.52) HSD11B1KMT2AALDH1A1MEN1MAPT
SCHEMBL4514429 0.81 HSD11B1 (0.52) HSD11B1GAAKMT2AALDH1A1MEN1
SCHEMBL3554331 0.79 HSD11B1 (0.60) HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
EP-1864971-A1 PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES Takeda Pharmaceutical Company Limited (JP) 2007-12-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes HSD11B1, HSD17B1, HSD11B2 HSD11B1 1/4885GAA 1261/4885TSHR 3390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.